Lung cancer
Conditions
Interventions
Training group:Based on the data of the training group, a risk prediction model for high-risk recurrence after MWA was constructed
internal validation group: preliminary validation of the accuracy of the model was carried out by the internal validation group.
External Validation Group:Fifty patients were prospectively enrolled as an external validation group for further validation of model accuracy
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
65 Years to 100 Years
Inclusion criteria
Inclusion criteria: ? Signed informed consent, age =65 years old; ? Pathologically confirmed diagnosis of lung cancer, early stage (AJCC 8th edition ?A, ?B, ?A stage, i.e., tumor diameter =5cm, no lymph nodes and distant metastasis) as determined by PET-CT, enhanced CT and other imaging; ? Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-3; ? Cannot tolerate or refuse surgery and radiotherapy; ? Primary treatment, in addition to supportive treatment, found residual tumor, recurrence, and radiation therapy; ? Primary treatment, in addition to supportive treatment, the age of =65 years old. Group Performance Status (ECOG PS) score 0-3; ? Inability to tolerate or refusal of surgery and radiotherapy; ? Primary treatment, in addition to supportive therapy, did not receive other adjuvant therapy before the discovery of tumor residuals, recurrence, and metastasis; ? The course of treatment cooperated with the provision of clinicopathological data, imaging data, etc. required for the study process, cooperated with the follow-up visits and collection of clinical efficacy assessment node blood, and agree to use the test data for subsequent research.
Exclusion criteria
Exclusion criteria: ?severe bleeding and coagulation disorders, platelets less than 50 × 109/L; ? Eastern Oncology Collaborative Group score > 3; ? severe systemic infection, high fever (> 38.5 ?), and skin infection and breakage at the puncture site; ?the combination of other malignant tumors; ? incomplete data or inability to comply with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| demographic information;follow-up endpoint;Median time to recurrence after MWA;progression-free survival (PFS);overall survival (OS) ; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS rate at one-year post MWA surgery;PFS rate at two-year post MWA surgery;OS rate at one-year post MWA surgery;OS rate at two-year post MWA surgery; | — |
Countries
China
Contacts
Public ContactXiao-guang Li
Beijing Hospital
Outcome results
None listed